拉莫三嗪联合丙戊酸钠治疗对癫痫患儿疗效改善不良事件及预后的影响研究

Effect of Lamotriazine Combined with Valproate on improving Adverse Events and Prognosis in Children with Epilepsy

目的研究拉莫三嗪联合丙戊酸钠治疗对癫痫患儿疗效改善不良事件及预后的影响。方法挑选本院收治的122例癫痫患儿,按数字表法分为两组,每组61例。对照组实施丙戊酸钠治疗,试验组实施拉莫三嗪联合丙戊酸钠治疗,分析比较两组患儿不良事件的发生情况,以及治疗前后疗效的改善情况和预后情况。结果对比两组治疗前癫痫发作的次数,无差异(P> 0.05);与治疗前比,治疗3个月及半年后两组癫痫发作的次数均明显下降,且试验组少于对照组(P <0.05)。试验组不良事件总发生率远低于对照组(P <0.05)。比较两组治疗前、治疗3个月及半年后的HDL-C水平,无差异(P> 0.05)。对比两组治疗前的TC及TG水平,无差异(P> 0.05);与治疗前比,两组治疗3个月及半年后的TC及TG水平均显著上升,且试验组高于对照组(P <0.05)。结论对癫痫患儿实施拉莫三嗪联合丙戊酸钠治疗,能有效降低患儿癫痫发作的次数和不良事件的发生,还能明显改善患儿的TC及TG水平,疗效改善情况及预后情况良好,值得临床推广。

Objective To study the effect of lamotriazine combined with valproate on the improvement of outcomes and outcomes in children with epilepsy.Methods One hundred and twenty-two epileptic children were selected and divided into two groups, 61 in each group. The control group was treated with valproate, and the experimental group was treated with lamotriazine and valproate, and the occurrence of adverse events in the two groups of children was analyzed and compared, as well as the improvement of efficacy and prognosis before and after treatment. Results There was no difference in the number of pretreatment seizures between the two groups(P >0.05). Compared with the pre-treatment group, the number of seizures in the two groups decreased significantly after three months and six months, and the experimental group was less than the control group(P<0.05). The total incidence of adverse events in the experimental group was much lower than in the control group(P <0.05). There was no difference in HDL-C levels between the two groups before treatment, three months after treatment, and six months after treatment(P >0.05). There was no difference in the levels of TC and TG before treatment between the two groups(P >0.05). Compared with the pre-treatment, the average levels of TC and TG in the two groups after three months and six months of treatment increased significantly, and the experimental group was higher than the control group(P<0.05). Conclusion Lamotriazine combined with valproate can effectively reduce the incidence of seizures and adverse events in children with epilepsy. It can also significantly improve the levels of TC and TG in children, and improve the efficacy and prognosis. It is worth clinical promotion.